HRS-7053
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 25, 2025
Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | N=186 ➔ 0 | Trial completion date: Jun 2027 ➔ May 2025 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Jun 2027 ➔ May 2025
Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Hematological Malignancies • Oncology
August 09, 2023
Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies
(clinicaltrials.gov)
- P1 | N=186 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Metastases • New P1 trial • Hematological Malignancies • Oncology
1 to 2
Of
2
Go to page
1